Clinical Trials Logo

SARS Pneumonia clinical trials

View clinical trials related to SARS Pneumonia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04315480 Active, not recruiting - SARS Pneumonia Clinical Trials

Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis

Start date: March 12, 2020
Phase: Phase 2
Study type: Interventional

In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking deterioration of lung function or even promoting a rapid improvement of clinical conditions, preventing naso-tracheal intubation and/or death.